Edison is a content-led IR business on a mission to build bigger, better and more engaged investors for our clients.

Joined February 2010
2,567 Photos and videos
discoverIE Group — Positive momentum for FY27 discoverIE’s FY26 results confirmed a return to organic revenue growth, and the company reported financial performance in line with expectations. #LSE $DSCV 📖 Read full analysis here: edisongroup.com/research/pos…
67
Molten Ventures — ICEYE funding round triggers over 200% uplift @MoltenVentures' FY26 results (to end-March 2026) confirmed the key highlights from its FY26 trading update published in April 2026 #LSE $GROW 📖 Read full analysis here: edisongroup.com/research/ice…
86
The Platform Group — A strong start to FY26 The Platform Group (TPG) delivered strong growth in revenue, with all KPIs moving in the right direction #FRA $TPG0 📖 Read full analysis here: edisongroup.com/research/a-s…
197
Cereno Scientific — Multiple catalysts set the stage for a re-rating 2026 is shaping up to be a pivotal year for @CerenoSciAB, with Q126 milestones further de-risking the pipeline. #OMX $CRNO 📖 Read full analysis here: edisongroup.com/research/mul…
3
3
151
Leading Edge Materials — Exceptional DyTb exposure at a hefty discount @LeadingEdgeMtls offers differentiated European exposure to scarce heavy rare earths through its 100%-owned Norra Kärr project in Sweden. #TSX $LEM 📖 Read full analysis here: edisongroup.com/research/exc…
106
Supermarket Income REIT — Dividend growth from firm foundations @SupermarketREIT operates in a structurally supported, growing sector, significantly insulated from macroeconomic uncertainty. #LSE $SUPR 📖 Read full analysis here: edisongroup.com/research/div…
90
OSE Immunotherapeutics — Set for a strategically important year @OSEImmuno ($OSE) has published its FY25 results, reaffirming its strategy of streamlining its clinical pipeline to focus on its core assets #PAR 📖 Read full analysis here: edisongroup.com/research/set…
1
183
Braemar — Potential rewards on the voyage to 2030 Braemar’s FY26 results were in line with company expectations against a challenging market backdrop. $BMS 📖 Read full analysis here: okt.to/nIsBgC
120
Bally’s Intralot’s (BI’s) recommended all-share offer for evoke materially scales the group’s total addressable markets, exposure to B2C (including its first presence in retail), net debt position and enterprise value. $BYLOT 📖 Read full analysis here: okt.to/O3JIPc
78
Thrive Renewables’ FY25 results reflect the expected normalisation of UK electricity prices, weak Q1 wind resource and a £4.0m exceptional impairment against a third-party construction loan. $THRV @Thrive_R 📖 Read full analysis here: okt.to/3UOAhB
78
International Airlines Group’s investor day highlighted how IAG Loyalty has evolved to become one of IAG’s core strategic assets… $IAG 📖 Read full analysis here: okt.to/UZASNn
124
Pan American Silver — Growth, returns and discipline Pan American Silver’s 2026 investor day reinforced a strategy centred on self-funded organic growth, disciplined capital allocation and enhanced shareholder returns. $PAAS 📖 Read full analysis here: okt.to/QBp6YP
138
The Metals Company announced on 28 May 2026 the achievement of a key milestone in the regulatory approval process as the NOAA has certified the USA B licence application made by TMC’s subsidiary, TMC USA, covering c122,000km2 of seafloor. $TMC @themetalsco okt.to/P2EcoT
3
443
Patria Private Equity Trust — Key takeaways from the 2026 CMD Patria Private Equity Trust’s (PPET’s) recent capital markets day (CMD) was an opportunity to reiterate the trust’s main attractions. $PPET 📖 Full analysis: okt.to/om29iX
104
Games Workshop Group — A good beat for FY26 Games Workshop Group’s FY26 trading update indicates another year of strong growth, beating our prior estimates. $GAW @warhammer 📖 Full analysis: okt.to/R7PqoY
1
351
British American Tobacco — New Categories accelerating British American Tobacco’s (BAT’s) H126 trading update confirms the company is on track to deliver underlying operational guidance for the year. $BATS @BATplc 📖 Full analysis: okt.to/pA6wH1
130
Herantis Pharma — FDA feedback clears HER-096 Phase IIa path Herantis Pharma has announced positive FDA feedback and finalised the Phase IIa design for HER-096 in Parkinson’s disease (PD). $HRTIS @HerantisPharma 📖 Full analysis: okt.to/Wj6g1H
1
155
CI Games — Q126 solid, but all eyes on H2 Q126 was always going to be a relatively quiet period for the group, with investor attention growing as the year progresses. $CIG @CIGamesOfficial 📖 Full analysis: okt.to/YSB0kj
1
96